Dr. Katie Murray discusses the diagnosis and management of non–muscle invasive bladder cancer, emphasizing cystoscopy and initial TURBT as the standard for accurate diagnosis and pathology. She notes that low-grade bladder cancer has a high recurrence rate, often within the first year. Traditionally, recurrences required repeat surgery, but newer FDA-approved intravesical chemoablative therapies now offer an alternative. These options may help some patients avoid returning to the operating room while effectively treating recurrent disease.
ZUSDURI (Mitomycin) Demonstrates Sustained Efficacy Across EORTC Risk Groups in Recurrent NMIBC
ZUSDURI (mitomycin) delivers durable tumor control in recurrent low‑grade, intermediate‑risk NMIBC, with 79.6% complete responses at three months and 72.2% event-free survival at 24 months. Effective across all EORTC risk groups, it offers a promising option for bladder preservation and long-term disease management.
